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Background: Considering the high number of new cases of cervical cancer each year that are caused by human
papilloma viruses (HPVs), the development of an effective vaccine for prevention and therapy of HPV-associated
cancers, and in particular against the high-risk HPV-16 genotype, remains a priority. Vaccines expressing the E6 and
E7 proteins that are detectable in all HPV-positive pre-cancerous and cancer cells might support the treatment of
HPV-related lesions and clear already established tumors.
Methods: In this study, DNA and fowlpox virus recombinants expressing the E6F47R mutant of the HPV-16 E6
oncoprotein were generated, and their correct expression verified by RT-PCR, Western blotting and immunofluorescence.
Immunization protocols were tested in a preventive or therapeutic pre-clinical mouse model of HPV-16 tumorigenicity
using heterologous (DNA/FP) or homologous (DNA/DNA and FP/FP) prime/boost regimens. The immune responses and
therapeutic efficacy were evaluated by ELISA, ELISPOT assays, and challenge with TC-1* cells.
Results: In the preventive protocol, while an anti-E6-specific humoral response was just detectable, a specific CD8+
cytotoxic T-cell response was elicited in immunized mice. After the challenge, there was a delay in cancer appearance
and a significant reduction of tumor volume in the two groups of E6-immunized mice, thus confirming the pivotal role
of the CD8+ T-cell response in the control of tumor growth in the absence of E6-specific antibodies. In the therapeutic
protocol, in-vivo experiments resulted in a higher number of tumor-free mice after the homologous DNA/DNA or
heterologous DNA/FP immunization.
Conclusions: These data establish a preliminary indication for the prevention and treatment of HPV-related tumors
by the use of DNA and avipox constructs as safe and effective immunogens following a prime/boost strategy. The
combined use of recombinants expressing both E6 and E7 proteins might improve the antitumor efficacy, and
should represent an important approach to control HPV-associated cancers.
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High-risk human papillomaviruses (HPVs) are the causa-
tive agents of cervical tumors, and are responsible for an
increasing frequency of anogenital and head and neck
tumors [1]. Although different HPV types are considered
as cancer-related agents [2], HPV-16 and HPV-18 are
the most frequent genotypes, and they are involved in
about 62.6% and 15.7% of cervical neoplasias, respect-
ively [3,4].
Preventive vaccines are the first choice for intervention
against HPVs, as they can hamper the primary infection
by eliciting neutralizing antibodies against the incoming
virus, and HPV virus-like-particles (VLPs) have already
been produced in different cell-based systems, which are
morphologically and immunologically similar to the na-
tive virions [5,6]. These VLPs have proven to be effective as
prophylactic bivalent (Cervarix®) [7] and quadrivalent
(Gardasil®) [8] HPV vaccines. However, no therapeutic
activity has been demonstrated against already-established
HPV-16 and HPV-18 genital lesions, and the long delay
before tumor development limits the assessment of their
efficacy in lowering HPV tumor incidence [9]. Moreover,
VLPs are type-specific and they generate a limited cross-
protection against the genotypes not included in the vac-
cine. There is therefore a pressing need for novel immune
approaches to prevent HPV-related tumors.
The two major HPV oncogenes, E6 and E7, show high
levels of protein expression [10,11] that can be main-
tained for many years. They both cooperate in the
immortalization of primary human keratinocytes [12],
which are the natural target cells of HPV in vivo, and
their combined activity is essential for the transformed
cell phenotype and the evasion of apoptosis [13,14].
They represent therefore ideal targets for immunother-
apy, as they contribute to the progression from initial
lesions to malignancy and are constitutively expressed in
HPV-associated cancers throughout the replicative cycle
of the virus. In particular, while E7 appears to be the
main promoter of tumor formation, E6 is required to en-
hance some of the more malignant aspects of tumori-
genesis [15].
Pre-clinical animal models already exist for E6/E7-based
vaccines, that can be utilized to design immunogens and
eradicate established tumors by challenging mice with
syngeneic tumor cells expressing these antigens [16]. These
therapeutic vaccines mainly aim at generating a T-cell-
specific immunity, rather than a humoral response, by
stimulating antigen presentation to CD8+ cytotoxic T
lymphocytes (CTLs), and CD4+ T helper T cells. When
expressed as an L2/E6/E7 fusion protein by genetic
DNA vaccines, they already proved to be able to control
tumor growth [17,18] through the induction of CTLs
targeted to cancer cells [19-21]. DNA-based vaccines
have emerged as an attractive approach, because of theirsafety and stability, and the possibility of their repeated
administration. They are also an efficient means to tar-
get dendritic cells, and thus to prime antigen-specific
CD4+ and CD8+ T-cell immune responses in vivo [22].
Due to their high immunogenicity, live recombinant
viral vectors have also been used as HPV vaccines, as
they facilitate the spread of antigens. These vaccines
have been explored in pre-clinical models [23,24], where
they showed protective and therapeutic antitumor effects
against E7-expressing tumors in vaccinated mice. They
were safe, well tolerated and could stimulate antigen-
specific antibody and CTL responses [25-28]. The atten-
uated modified vaccinia Ankara (MVA) co-expressing
E6/E7 and IL-2 as an adjuvant has also been shown to
be effective in Phase II clinical trials [29,30], but did not
enter into Phase III.
Viral recombinants have also been assessed using
heterologous prime/boost regimens to enhance their im-
munogenicity and to limit the induction of neutralizing
antibodies against the vector. Live virus-based recombin-
ant vaccines, either as VV, MVA [31,32] or adenoviruses
[33], can be successfully primed by E6/E7 DNA-based
genetic vaccines. Conversely, the use of the E6/E7 fusion
proteins to either prime or boost VV-based HPV vaccines
did not show any correlation between immunological and
clinical responses [28,34]. However, as MVA replication in
mammals is only partially abortive [35,36], the search for
alternative safe vectors is still ongoing.
Canarypox and fowlpox (FP) avian poxviruses have
been developed as novel recombinant vectors against
human infectious diseases, and as vaccines against HPV
in preclinical [37], but not clinical, studies. As their
replication is restricted to avian species [38], they repre-
sent safe immunogens that are permissive for entry and
transgene expression in most mammalian cells [39,40].
Avipoxviruses are also immunologically non cross-reactive
with VV, and can thus escape pre-existing immunity in
smallpox-experienced humans.
An in-vivo single-point E6 mutant of HPV-16, E6F47R,
has also been identified as defective for polyubiquitina-
tion and degradation of p53, which competes with the
endogeneous E6 [41]. By hampering the p53 degradation
both in vitro and in vivo, E6F47R changes the E6 onco-
protein into a suppressor of proliferation of HPV-
positive HeLa cells [42].
The aim of the present study was to generate prevent-
ive/therapeutic DNA-based and FP-based recombinant
vaccines that express the modified HPV-16 E6F47R gene,
and to determine their immunogenicity and efficacy by
different prime/boost immunization protocols. Their ef-
fects were evaluated in the C57BL/6 mouse model of
HPV-related tumorigenesis by immunizing groups of mice
before and after the challenge with TC-1* syngeneic
cancer cells. The animals were monitored for E6-specific
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trol of tumor growth and survival to establish the immune
correlates of protection and tumor reduction in the im-
munized animals.
Methods
Cells
Specific-pathogen-free primary chick embryo fibroblasts
(CEFs) were grown in Dulbecco’s modified Eagle’s me-
dium supplemented with 5% heat-inactivated calf serum
(Gibco Life Technologies, Grand Island, NY, USA), 5%
tryptose phosphate broth (Difco Laboratories, Detroit,
MI, USA), 100 U/ml penicillin and 100 mg/ml strep-
tomycin. CaSki cells, which contain multiple copies of
integrated HPV-16 DNA, green monkey kidney (Vero)
cells, normal human lung fibroblasts (MRC-5), and TC-
1 star (TC-1*) mouse cells (which constitutively express
the HPV-16 E6 and E7 oncoproteins, but are more ag-
gressive than TC-1 and have been shown to induce tu-
mors in 100% of the injected mice [43]), were grown in
Dulbecco’s modified Eagle’s medium supplemented with
10% calf serum and 100 U/ml penicillin and 100 mg/ml
streptomycin.
Construction of the pDNAE6F47R expression plasmid
The pDNAE6F47R expression plasmid was used for the
mice immunizations, and it contains the mutated E6F47R
sequence of the HPV-16 E6 gene [41,42]. The pX5-E6-
F47R/6C6S plasmid that contains the mutated E6F47R
gene was a kind gift from G. Travé (CNRS, University of
Strasbourg, Illkirch, France). This mutant was obtained
by replacing one phenylalanine (F) with one arginine
residue (R), and six cysteine (C) with six serine (S) residues.
The first mutation prevents p53 degradation, whereas the
C/S substitutions were introduced to minimize oxidation
and to stabilize the protein. Briefly, after excision from the
pX5-E6-F47R/6C6S plasmid using the EcoRI and NotI
enzymes, the E6-F47R/6C6S gene was inserted into the
pcDNA3 plasmid (Life Technologies Corp., Carlsbad, CA,
USA). This plasmid was propagated in Escherichia coli
XL1-Blue and extracted by alkaline lysis, followed by
plasmid purification with endotoxin removal (Qiagen,
EndoFree Plasmid Giga Kit, Hilden, Germany). After
dissolving this plasmid in Ca2+-free and Mg2+-free
phosphate-buffered saline (PBS−) to a final concentration
of 1 mg/ml, this was used for immunization of the mice.
Construction of the FPE6F47R recombinant virus
The recombinant FP virus expressing the E6F47R protein
(FPE6F47R) was obtained by in-vitro homologous recom-
bination [44]. Briefly, the genetically mutated E6F47R gene
of HPV-16 was amplified by PCR from the pcDNA3E6F47R
plasmid and inserted downstream of the VVH6 vaccinia
virus early/late promoter into the pFPMCS vector, whichcontained the 3-β-hydroxysteroid dehydrogenase 5-delta 4
isomerase gene and was interrupted by a multiple cloning
site [45]. The DNA sequence that encodes the E6F47R
region was amplified using the forward V364 (5′ CCG
CGC CCG GGA AGC TTA TGC ACC AAA AGA GAA
CT 3′) and the reverse V99 (5′ CGA AGC TTT TAC
AGC TGG GTT TCT CTA CG 3′) primers. The amplifi-
cation was carried out as described previously [46]. The
plasmid DNA was purified and the E6F47R was sequenced
(Bio-Fab Research, Rome, Italy) to exclude any possible
mutations arising from the PCR amplification and desig-
nated as pFPE6F47R (8,700 bp). The FPE6F47R recombinant
was obtained by in-vitro recombination on primary CEFs,
as described previously [47], using FP wild-type (FPwt)
and pFPE647R [48]. The recombinant clones were identi-
fied by autoradiography after hybridization with the [32P]-
labeled E6F47R probe, picked, and subjected to multiple
cycles of plaque purification. One clone was selected for
its correct and high expression of the E6F47R gene, as
determined by RT-PCR, Western blotting and immu-
nofluorescence using anti-E6-specific antibodies. The
FPE6F47R recombinant virus was amplified in CEFs,
purified on a discontinuous sucrose gradient, titered,
and used for mice immunization.
RT-PCR
Expression of the E6F47R gene in CEFs and Vero and
MRC-5 cells was investigated first using RT-PCR. The
cells were infected with one plaque-forming unit (PFU)/
cell of the FPE6F47R virus. Total RNA extraction was car-
ried out 24h post-infection, using Trizol LS (Gibco, Life
Technologies), and the mRNAs from all of the samples
were prepared as described previously [49]. Briefly,
50 ng RNA from each sample was used in a final volume
of 10 μl, in the presence of 1 μM of each primer,
200 mM of each dNTP, 0.1 U/μl Thermus flavus DNA
polymerase, 0.1 U/μl avian myeloblastosis virus reverse
transcriptase, and 2.5 mM MgSO4. The V348 (5′ CTG
CAA TGT TTC AGG ACC 3′) and V99 primers were
used. The reverse transcriptase reaction was performed
at 48°C for 45 min, followed by 2 min at 94°C. PCR
amplification was carried out for 40 cycles at 94°C for
30 s, 55°C for 30 s, and 68°C for 30 s, followed by a final
incubation at 68°C for 7 min. FPwt-infected cells were
used as negative controls, and the pFPE6F47R plasmid
was used as the positive control.
Western blotting
To determine whether the E6F47R protein was expressed
correctly, CEFs and Vero and MRC-5 cells were infected
with 10 PFU/cell FPE6F47R and examined by Western
blotting, as described previously [46]. The blotted nitro-
cellulose membranes were incubated overnight at 4°C
with 1:100 dilution of the primary rabbit AbE6/Mu
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search Center, Heidelberg, Germany). After a 1-h in-
cubation with a goat anti-rabbit horseradish peroxidase
(HRP) antibody (1:2000 dilution; DakoCytomation,
Carpinteria, CA, USA) and 2-h washes, the proteins
were revealed using the ECL system (GE Healthcare,
Buckinghamshire, UK). Cells infected with FPwt were
used as the negative control, and the E6 protein as the
positive control.
Immunofluorescence
To detect the expression of the E6F47R protein, immuno-
fluorescence was also carried out on CEFs and Vero and
MRC-5 cells infected with 5 PFU/cell, as described pre-
viously [48]. The expression of the E6F47R gene was also
verified after transfection with the pcDNA3E6F47R plas-
mid by the PolyJet™ transfection reagent (SignaGen Lab.,
Rockville, MD, USA). Briefly, cells were overlaid with
1 μg reagent in 1.1 ml medium per 4-cm-diameter Petri
dish without serum and antibiotics for 16–24 h, and
replaced with the complete medium for an additional
24 h. The samples were then treated for 1 h with the
1:100-diluted mouse AbE6/Gi or with the 1:300-diluted
rabbit Rpool polyclonal antibodies, obtained in our la-
boratory [50] followed by the 1:100-diluted FITC-labeled
goat anti-mouse or sheep anti-rabbit sera (DakoCytoma-
tion) for 1 h. FPwt and pcDNA3 empty plasmid were
used as the negative controls to infect or transfect the
different cell lines. The samples were viewed under a
Zeiss Axioskop fluorescence microscope.
Production of wild-type E6 protein in its native form in
bacteria
The pQE30 expression plasmid (Qiagen) was engineered
to contain the E6 gene of HPV-16, which is referred to as
pQE30-E6/His, inserted in E. coli (strain M15, Qiagen),
and the protein was prepared under non-denaturing
conditions. Briefly, after 16h of growth, the culture was
100-fold diluted in fresh Luria-Bertani broth with 25 μg/
ml kanamycin and 100 μg/ml ampicillin, and incubated at
37°C until an OD600 of 0.6-0.7 was reached. Protein ex-
pression was induced with 1 mM isopropyl-β-D-thio-
galactopyranoside. The cells were maintained at 28°C for
16 h, and then harvested by centrifugation at 4,000× g for
20 min at 4°C. The pellet was resuspended in lysis buffer
(50 mM NaH2PO4, 200 mM NaCl, 20 mM imidazole,
100 μM dithiothreitol [DTT], pH 7.5) containing an
EDTA-free anti-protease cocktail (Roche, Basel, Switzerland)
at the concentration recommended by the manufacturer.
After adding 1 mg/ml lysozyme and 1% Triton X-100, the
cells were incubated for 1 h at 4°C and then sonicated on
ice at a 10-Hz output (3 times for 1 min). Clarification
was performed by centrifugation at 15,000× g for 45 min
at 4°C, and the supernatant was incubated for 16 h with1 ml Ni-nitrilotriacetic acid agarose resin (Qiagen) that
had been pre-equilibrated in lysis buffer. After washing
several times with 50 mM NaH2PO4, 200 mM NaCl,
70 mM imidazole, 100 μM DTT, pH 7.5, to a final OD280
of 0.01, the protein was eluted in different fractions using
50 mM NaH2PO4, 200 mM NaCl, 300 mM imidazole,
100 μM DTT, pH 7.5, and run on 12% SDS-PAGE. The
fractions enriched in the recombinant proteins were
pooled, quantified, and stored at 4°C until use. The puri-
fied E6 protein (pE6) was dialyzed in PBS− containing
betaine (0.02%) and DTT (100 μM), and used for the
enzyme-linked immunosorbent assays (ELISA).
Immunization protocols and challenge with TC-1* tumor
cells
In the preventive protocol (Figure 1A), three groups of
six 6-week-old female C57BL/6 mice (Charles River
Laboratories, Como, Italy) were vaccinated by multiple
injections. The mice were primed with the recombinant
pDNAE6F47R plasmid once (protocol G1; 100 μg/mouse,
intramuscular, i.m.) or twice (protocol G2; 100 μg/mouse,
i.m.). Two weeks after the DNA inoculation, they were
boosted twice (protocol G1) or once (protocol G2) with
FPE6F47R (10
7 PFU/mouse, subcutaneous, s.c.). All of
the mice remained in good health, and, after the last
immunization, half of the mice of each group were
sacrificed to perform the enzyme-linked immunospot
(ELISPOT) assays. All of the other mice were challenged
by a s.c. injection of 5 × 103 E6/E7-expressing TC-1*
syngeneic tumor cells in 200 μl saline solution [43]. The
control mice (Figure 1, protocol G3) were repeatedly mock
infected and tumor growth was monitored twice a week
until tumor appearance, and every day thereafter by visual
inspection and palpation.
In the therapeutic protocol (Figure 1B), four groups of
five mice were challenged by s.c. injection with TC-1*
cells (5 × 103 in 200 μl saline solution). Three and ten
days after challenge, the mice were immunized twice with
DNAE6F47R (protocol G1; 100 μg/mouse, i.m.) or with
DNAE6F47R followed by FPE6F47R (protocol G2; 10
7 PFU/
mouse, s.c.) or twice with FPE6F47R (protocol G3; 10
7
PFU/mouse, s.c.). The mice for protocol G4 were mock
vaccinated and used as controls. Tumor growth was mon-
itored by visual inspection and palpation twice a week.
Animals were scored as tumor-bearing when tumors
reached a size of approximately 1 to 2 mm in diameter.
Animals were euthanized for ethical reasons when tumors
reached a volume of about 4-cm3, as calculated by the for-
mula “length × width2 × 0.5”. All of the mice were housed
and handled under specific-pathogen-free conditions at
the Animal House of the Regina Elena Cancer Institute
(Rome, Italy) upon the approval of local Ethical Com-
mittee, in accordance with the European Guidelines
no. 86/609/CEE and 116/92 for the protection of laboratory
boostprime challenge  
boostprime challenge
mock challenge
challenge prime boost
Figure 1 Immunization protocols. For the preventive response (A), six mice per group were used to evaluate the immune responses and the
protection of the vaccinated mice. Half of the mice for each group were challenged with syngeneic tumor TC-1* cells, while the remaining mice
were used for spleen removal and ELISPOT assays for the cell-mediated immune responses. For the therapeutic immunization (B), five mice were
challenged with TC-1* cells, primed once three days after challenge, and boosted one week after the priming. Black triangles, times of mice
bleeding; arrows, vaccine administration and challenge.
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of Health, Department for Veterinary Public Health,
Nutrition and Food Security, Protocol 17/2006).
ELISA
The ELISA was essentially performed as described previ-
ously [51], using either the purified native pE6 protein
or the CaSki cells as the plate-bound antigen. Briefly,
96-well maxisorp microtiter plates (Nunc, Naperville, IL,
USA) were coated with pE6 (300 ng/well) in PBS− or
with CaSki lysates (105 cells/well) in 0.05 M carbonate–bi-
carbonate buffer, pH 9.6, and incubated overnight at 4°C.
CaSki cells were disrupted by freeze-thawing three times
and MRC-5 cells were used as a negative control. The sera
were then added at a 1:50 dilution, and the binding was
revealed by a 1:2000 dilution of goat anti-mouse HRP-
conjugated sera (Dako) and tetramethylbenzidine sub-
strate (Sigma-Aldrich Italia, Milan, Italy). The absorbance
for each well was measured at 450 nm with a 550 micro-
plate reader (Bio-Rad Laboratories, Hercules, CA, USA).
ELISPOT assay for interferon-γ-secreting cells
HPV-16 E6-specific T-cell precursors were detected
using ELISPOT assays for IFN-γ-secreting cells (BD™
ELISPOT, BD Biosciences Pharmingen, San Diego, CA,
USA) [52]. Briefly, the mice were euthanized by cervical
dislocation one week after the last immunization. A
single-cell suspension of splenocytes harvested from the
mice from each group was added to microtiter wells (106
cells/well) that had been pre-coated overnight at 4°C with
an anti-mouse-IFN-γ antibody (5 μg/ml; BD Biosciences
Pharmingen) along with IL-2 (50 units/ml; Sigma). Stimu-
lation was performed in triplicates at 37°C for 24 h to
72 h, either with three different concentrations of pE6
(0.1, 1.0, 10 μg/ml) or with two E6-specific epitopes (aa
50–57, aa 18–26) [53,54], to detect the T-cell precursors.
A mixture of phorbol myristate acetate and ionomycin
was used to detect responsive cells. An unrelated protein
(scFv), a single chain recombinant antibody produced in
our laboratory with a procedure similar to the one used
for the E6 protein, was used as a negative control. The
plates were incubated with a biotinylated anti-mouse
IFN-γ antibody (2 μg/ml; BD Biosciences Pharmingen)
for 4 h at room temperature. Streptavidin-HRP was then
used for 1 h at room temperature, and the cell spots
were stained by addition of 3-amino-9-ethylcarbazole
substrate for 1 to 5 min. The spots were counted under
a dissecting microscope.
Statistical analyses
Statistical analyses were performed using one-way ANOVA
parametric tests and Bonferroni analysis of variance, using
the GraphPad Prism 5 software. Statistical significance
was set as p <0.05 (*), p <0.01 (**), p <0.001 (***).Results
The FPE6F47R and the pDNAE6F47R recombinants correctly
express the E6F47R transgene
RT-PCR of RNAs from FPE6F47R-infected CEFs and
Vero and MRC-5 cells showed amplification of a 477-bp
band (Figure 2A, lanes B) that corresponds to the E6
transcript. The pFPE6F47R plasmid was used as a positive
control (Figure 2A, C+). FPwt-infected cells were always
negative (Figure 2A, lanes A), as well as samples proc-
essed in the absence of reverse transcriptase (data not
shown).
Western blotting of FPE6F47R-infected CEFs and Vero
and MRC-5 cell lysates showed a 19-kDa oncoprotein
band (Figure 2B, lanes B). No bands were seen when
these cells were infected with FPwt (Figure 2B, lanes A).
The nonmutated E6 protein produced by an engineered
bacterial vector was used as a molecular weight control
marker (Figure 2B, lane C). The E6F47R protein was ex-
pressed at higher levels by CEFs (5.8-fold) and Vero cells
(4.4-fold) than by MRC-5 cells, as determined by densito-
metric analysis.
After FPE6F47R infection (Figure 2C; 1b, 2b, 3b and 1c,
2c, 3c) or pDNAE6F47R transfection (Figure 2C; 1d, 2d, 3d),
immunofluorescence was detectable in CEFs and Vero and
MRC-5 cells using either the mouse AbE6/Gi or the rabbit
Rpool polyclonal antibodies, with granular nuclear and
perinuclear/cytoplasmic localization. FPwt-infected cells
were negative, as expected (Figure 2C; 1a, 2a, 3a).
The E6-specific humoral response is very low in vaccinated
mice
The immunized mice were tested for E6-specific humoral
immunity. The antibody response against E6 was mea-
sured using ELISA, with plates coated with either the
native purified recombinant pE6 protein or the CaSki cell
lysates. The mice sera were analyzed before the first
immunization (T0), after the first boost (T2), and before
the challenge (T3), but the antibody responses were gener-
ally low, both when using the E6 protein or CaSki cell
lysates (data not shown).
E6-immunized mice show a CD8+-specific cellular response
IFN-γ-secreting spot-forming cells (SFCs) were counted
using splenocytes obtained after the third immunization
from the mice that were not challenged. The mean of
the SFCs was assessed after subtracting the number of
IFN-γ-positive cells stimulated with the unrelated scFv
protein, that can be considered the splenocyte stimula-
tion resulting from the LPS content of the protein. An
increase in IFN-γ-producing cells was seen for both of
the G1 and G2 immunization protocols (see Figure 1),
above the level observed in the mock-vaccinated mice of
protocol G3 (Figure 3). In particular, when the splenocytes
were stimulated with the E6 protein, protocols G1 and G2
transfectioninfection
Figure 2 Expression of the E6F47R in replication-permissive avian and replication-restrictive mammalian cells. RT-PCR was used to amplify
the 477-bp E6-specific transcripts in all of the cell types (A, lanes B). FPwt-infected cells were used as negative controls (A, lanes A) and the
plasmid pFPE6F47R as a positive control (C
+). M; 100-bp ladder. Western blotting was used to reveal the presence of a 19-kDa protein in cells
infected by FPE6F47R (B, lanes B) using the rabbit AbE6/Mu polyclonal antibody. FPwt-infected cells (B, lanes A) and the E6 protein (B, lane C) were
used as a negative or positive controls, respectively. By immunofluorescence (C), specific staining was detectable in all cell lines after infection
with FPE6F47R (C; 1b, 2b, 3b and 1c, 2c, 3c) or transfection with pDNAE6F47R (C; 1d, 2d, 3d) recombinants, using either the mouse AbE6/Gi or the
rabbit Rpool polyclonal antibodies. FPwt-infected cells were negative (C; 1a, 2a, 3a), as well as the pcDNA3-transfected cells, as expected
(data not shown).
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E6-specific aa 50–57 peptide was used, this increase was
even higher for G1 and for G2 vs G3 (p <0.001). The same
results were obtained when the aa 18–26 peptide was
used, with a major increase for G1 (p <0.001 vs G3) com-
pared to G2 (p <0.01 vs G3).
Preventive immunization delays tumor appearance and
reduces tumor growth
The immunized mice were challenged with syngeneic
TC-1* cells two weeks after the last boost, and thenregularly examined for tumor growth. Tumor growth
first appeared 10 days post-challenge (p.c.) in all of the
mice under protocol G3 (Table 1), whereas, in the mice
under the G1 and G2 immunization protocols, tumor
growth was delayed to 16 days p.c. At 20 days p.c., all of
the mice were still alive, although the data on their
further survival were not collected thereafter, as they
were euthanized for ethical reasons. A clear difference in
the tumor volume was found for the cancer-bearing
mice that followed protocols G1 and G2 vs protocol G3.
In particular, the tumor size was significantly lower in
Figure 3 Functional virus-specific T-cell responses to E6. IFN-γ production was measured in an ELISPOT assay after preventive immunization
to detect CD8+ T-cells after specific antigenic stimulation with the E6 protein and peptides. The numbers of IFN-γ-secreting spot-forming cells
(SFCs) were determined after subtracting the values obtained using the scFv unrelated protein. Data are presented as fold-increased responses to
the E6-specific protein and peptides. G2 and G3 are the protocols for the DNA/FP and FP/FP prime/boost vaccinations, respectively. Statistical
significances using the ANOVA parametric test are shown: **p <0.01; ***p <0.001.
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day 23 p.c. (p <0.05).Therapeutic immunization with DNA/FP recombinants
delays tumor growth
After injecting the TC-1* cells into naïve mice, prime/
boost immunizations were performed on days 3 and
10, respectively (Figure 1B). The number of tumor-
bearing animals was significantly lower in immunized
mice compared to the control (Figure 4, G1, G2, G3
vs G4, p <0.001). Tumor appearance was delayed to
day 21 p.c. in 20% of mice of G1 and G3, and to day
27 p.c. in 40% of the animals of G2. Tumor develop-
ment was seen in 80% of the mice at day 17 p.c. in
G4, and at day 34 and 31 p.c. in G2 and G3. At day
54, only 20% of the animals of G1 developed tumors,
whereas cancer-bearing mice remained 80% in G2 and
G3. The numbers of healthy mice remained higher in G1,
when compared to both G2 and G3. Statistical analyses
also indicate a significant difference between G2 vs G1
(p <0.05) and G3 vs G1 (p <0.01).Table 1 Inhibition of tumor growth after preventive
immunization
Tumor appearance
(days p.c.)
Mean tumor volume
23 days p.c. (cm3 ± SD)
G1 16 2.52 ± 0.7
G2 16 1.96 ± 0.4*
G3 10 3.36 ± 0.2
p.c., post challenge.
*p <0.05 G2 vs G3, by the one-way ANOVA parametric test.Discussion
Although most HPV vaccines have to date focused on
the E7 oncogene, E6 also represents a target for poten-
tial vaccine development to control HPV-associated le-
sions [14]. E6 is co-expressed with E7 in the majority of
HPV-associated tumors, and is responsible for the full
malignant transformation through its association with
cellular target proteins [1]. However, E6 is poorly im-
munogenic in the C57BL/6 mouse model and the use of
a mutated version of the gene is essential to minimize
the safety concerns for DNA and FP vaccines translation
to the clinic.
In the present study, we have described the construc-
tion of new genetic and FP recombinants that express
the mutated non-oncogenic HPV-16 E6F47R protein to
be used in combination as a preventive/therapeutic anti-
tumor vaccine. When expressed in HPV-positive cervical
cancer cells, E6F47R acts as a dominant-negative mutant
by counteracting the p53 degradation activity of the
endogenous E6, and thus restores high p53 protein
levels [41,42].
After animal immunization, both the humoral and
cell-mediated immune responses were evaluated, as well
as their correlation with tumor-size reduction or delay
in tumor development to prove the therapeutic efficacy.
Our results demonstrated that: (i) the pDNAE6F47R as
well as FPE6F47R recombinants can correctly express the
E6F47R protein in different cell lines; (ii) the CD8
+ T cell
response was higher in the mice immunized with the E6
recombinants using the G1 and G2 protocols; (iii) in the
preventive immunization, after challenging with TC-1*
cells, tumor appearance was delayed, and the tumor
Figure 4 Tumor growth after therapeutic immunization. Mice were challenged with TC-1* cells and immunized twice at day 3 and 10 p.c.
Immunization was performed with DNA/DNA (G1), DNA/FP (G2), and FP/FP (G3) recombinants expressing the E6F47R. The mice of group 4 were
mock vaccinated. Tumor growth was monitored by visual inspection and palpation. Animals were euthanized when the tumors reached a
4-cm3 volume.
Bissa et al. Journal of Translational Medicine  (2015) 13:80 Page 9 of 12volume was lower at day 23 p.c. in the mice under the
G1 and G2 protocols, compared to the G3 control
group; (iv) in the therapeutic immunization, the num-
bers of healthy animals remained higher after the DNA/
DNA regimen, but tumor appearance was delayed in all
of the protocols and was more evident by the prime/
boost DNA/FP schedule.
The amounts of the transcripts expressed by FPE6F47R
in all of the cell lines were similar, whereas a different
protein expression level was seen by Western blotting.
This cannot be ascribed to a lower efficiency of the
E6F47R gene expression by the FP vector, as protein ex-
pression was evident in all of the infected cells using
immunofluorescence. In CEF, as well as in the positive
control, an extra-band was seen, also described in other
studies [11,55]. Although this might be due to an already
observed splicing process [56], this cannot be the case of
FP viruses that replicate in the cytoplasm. The presence
of an additional ATG, downstream the initial starting
codon [11], can in fact result in the synthesis of a lower-
MW E6 (151 aa, around 18 kDa) in some cell lines such
as in CaSki cells, besides the full length E6 protein (158
aa, around 19 kDa). No significant differences were ob-
served by immunofluorescence after infection or trans-
fection with FPE6F47R or pDNAE6F47R.
The numbers of IFN-γ-secreting cells was significantly
higher after immunization with the E6 recombinants,
which are essential in clearing TC-1* tumor cells. Sur-
prisingly, although the aa 18–26 subdominant epitope
may contribute only slightly to the antitumor effect [54],
a higher response by the IFN-γ-producing splenocytes was
detected to this peptide in the G1 vs G2 immunizationprotocol. HPV-16 E6 epitope mapping [10] revealed that
the aa 50–57 region represents the minimal core sequence
essential for E6-specific CTL activity, and that the aa
48–57 peptide is the optimal immunodominant sequence.
The E6 aa 50–57 deletion prevented protection of TC-1-
challenged mice from a DNA vaccine [53,57], and it is to
be noted that the E6 aa 48–57 peptide contains CTL
epitopes that are presented by E6-expressing TC-1 cells.
Although it has still not been determined which HLA-
A24-restricted epitope is the most immunogenic one and
the most suitable for immunotherapy, a novel potent
HPV-16 E6 aa 66–74 peptide has recently been reported,
that can be used in vitro as an efficient means of
CTL induction [57] to discriminate between the different
immunization regimens.
After the preventive immunization and the TC-1* chal-
lenge, mice remained tumor-free up to 10 days, and tumor
appearance was delayed up to 16 days in the animals of
groups 1 and 2. Also, when the tumor developed, its vol-
ume was significantly smaller compared to the controls,
thus indicating the role of the CTL response.
After the therapeutic immunization, tumor growth
was also delayed in mice of groups 1, 2, and 3, with 80%
of still-healthy animals at 21 days p.c., when 100% of the
control animals (group 4) developed tumors. In particu-
lar, the numbers of healthy animals remained higher
after the DNA/DNA protocol, which should therefore be
considered the most effective regimen. However, although
genetic vaccination have emerged as an attractive strategy
for immunotherapy, in studies performed in non-human
and human primates, DNA vaccines suffered from low
immunogenicity and efficacy.
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protection can be obtained when animals are primed
with recombinant DNA followed by recombinant FP
boost than when using FP recombinants alone [37,52].
In the present study, we tested both DNA/FP and FP/FP
prime/boost immunization regimens. Although the re-
peated use of DNA for priming (G2) or FP for boost
(G1) gave similar results in the preventive immunization,
a difference was noted between group 2 and group 3 in
the therapeutic immunization when using DNA/FP ra-
ther than FP/FP. This suggests that DNA prime followed
by the FP boost can be a better strategy to induce CTLs,
kill tumor cells, and be effective in eliciting anti-tumor
immune responses in humans.
Many HPV vaccine strategies have focused on eliciting
HPV E6- and E7-specific T-cell responses, and several
vaccination trials have been performed on patients with
cervical cancer, genital warts and papillomas [58,59] also
to improve antigen processing and presentation [60,61].
In this context, a partial tumor regression was obtained
in the rabbit model by VSV-based vaccines encoding the
E6 or UbE6 [62,63] and a potent antitumor effect was
induced by administering mice with DNA vaccines en-
coding HPV-16 E6, E7 and L2 proteins fused to calreti-
culin [61], some of which are also in clinical trial [64].
An E7 DNA vaccine was shown to be ineffective in the
TC-1* mouse model, whereas the same gene linked to
immunostimulating functions such as the potato virus X
coat protein sequence [65] or fused to Zera® peptide [66]
showed a strong antitumor activity or tumor regression.
However, vaccines expressing the E6 gene alone have
not previously been tested for therapeutic efficacy in
prime/boost protocols.
Due to their natural restricted replication to avian
species [38], their correct expression of transgenes in
mammalian cells, and their ability to elicit a complete
immune response in vaccinated hosts [67], FP recombi-
nants represent alternative and safer immunogens than
VV, which can cause lytic infection, ulceration, and scab
formation. Our observations that a DNA/FP vaccination
schedule with E6-based non-adjuvanted vaccine can sig-
nificantly enhance the E6-specific CD8+ T-cell response
and partially control the growth of E6-expressing tumor
cells strengthen the effectiveness of this prime/boost
strategy and the importance of CTL response for tumor
inhibition.
Conclusions
This study aimed at verifying the immunogenicity in-
duced by a preventive vaccine expressing the HPV-16
E6F47R protein and the therapeutic efficacy of different
immunization protocols after challenging mice with
TC-1* cells. By the preventive immunization protocol,
our data show a delay in tumor appearance and areduction in tumor volume in the two groups of immu-
nized animals and establish the pivotal role of CTLs for
tumor inhibition. By the therapeutic immunization, after
challenging with TC-1* tumor cells, the number of healthy
animals remained higher after the DNA/DNA protocol,
but an evident delay of tumor growth was observed using
the DNA/FP protocol. Although a better efficacy was
expected, it is our hope that the combined use of recombi-
nants expressing both E6 and E7 proteins using the DNA
prime/FP boost strategy might improve the antitumor
effects. This should represent an important approach to
control HPV-associated cancers and we cannot exclude
that these vaccines might also be used for therapy in
already-infected but still-healthy subjects.
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